Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2009

View Archived Issues

Cytos reports patient allergy diary results from phase II CYT003-QbG10 study

Intra-Cellular reports top-line phase II ITI-007 results in insomnia

MediciNova reports phase II MN-221 data from emergency department study

Fornix reports 1-year follow-up results from clinical study of Oralgen in hay fever

FDA approves Alcon's IND application for NovaBay's NVC-422 for eye infections

Modigene reports results from pilot toxicity study of hGH-CTP in primates

FDA accepts for review ISTA's NDA for Bepreve for allergic conjunctivitis

Acceleron selects ACE-536 as new development candidate for anemia

Mologen reports successful results from ongoing phase I clinical trial of MGN-1703 for cancer

SIGA receives favorable guidance from EMEA regarding marketing authorization for ST-246

Benefit seen with multi-herbal product Yi-Gan San in vascular dementia patients

Phase II studies assess poly-ICLC in glioblastoma, anaplastic glioma

WHIMS-MRI Study evaluates effects of hormone therapy on brain volume, lesions

HDL nanoparticles synthesized

Copernicus and the University of Kentucky to collaborate on DNA therapy for PD

The Medicines Company to acquire Targanta Therapeutics

Analgesic calcium channel alpha2-delta subreceptor ligands claimed by Kyowa Hakko Kirin

iBioPharma reports results from preclinical animal studies of H5N1 subunit vaccine

Novel mgluR5 positive allosteric modulators developed at GSK for schizophrenia

DiaMedica cleared to commence second phase II DM-71 trial in type 2 diabetes

Scientists at Janssen describe new analgesic FAAH inhibitors in recent patent

Genentech to initiate pivitol phase II hedgehog pathway inhibitor trial in BCC

Peptimmune grants Novartis exclusive option to license PI-2301 for MS

Yakult launches anticancer drug Elplat 50 mg in Japan

Novel K(ATP) channel blockers claimed for cardiovascular disorders by sanofi-aventis

Novel protein kinase inhibitors with anticancer properties disclosed by Takeda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...